AI Drug Discovery for Pharma and Biotech

Drug discovery

24

papers

On emerging therapies

Overview

Monosomy 18q (18q deletion syndrome) is a rare genetic disorder caused by partial deletion of chromosome 18's long arm, spanning proximal (18q11.2-q21.2) or distal (18q21-qter) regions. Key features include developmental delay, intellectual disability, hypotonia, growth hormone deficiency, seizures, and structural anomalies (e.g., craniofacial dysmorphism, aural atresia, foot deformities). Phenotype severity correlates with deletion size and affected genes like TCF4 (linked to severe neurodevelopmental outcomes). Management requires multidisciplinary care [1][5][6][15].

Population

  • Estimated incidence: 1 in 55,000 live births [1][6]

  • Over 100 cases reported since 1964, with distal deletions more common than proximal [5][6][15]

Burden

  • Chronic medical needs: 64-80% require growth hormone therapy, 15% develop thyroid dysfunction, and 49% have hearing loss [8][15]

  • High healthcare utilization: Frequent specialist visits, imaging (MRI for dysmyelination), and hospitalizations for respiratory/pulmonary complications [3][10]

  • Lifespan: Near-normal except in deletions involving TCF4 (Pitt-Hopkins-like phenotype) [8][17]

Therapies

  • Multidisciplinary care: Early developmental interventions (PT/OT/speech therapy), growth hormone replacement for deficiency, and antiepileptics for seizures [5][8][13]

  • Surgical corrections: Cleft palate repair, aural atresia management, and orthopedic interventions for foot anomalies [6][8][13]

  • Symptom-specific approaches: Autism/ADHD therapies, nutritional support, and cardiac/renal monitoring [3][8][15]

Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare ophthalmic disorders, rare otorhinolaryngological diseases, rare surgical maxillo-facial diseases

Research Papers

24 drug discovery papers about Monosomy 18q. Recent publications:

24 drug discovery papers about Monosomy 18q. Recent publications:

categories:

Small molecules

gene therapies
2026-01-01 | De Grouchy Syndrome (18q Deletion): A Rare Case with Clinical and Genetic Insights

De Grouchy syndrome is a rare chromosomal disorder caused by the deletion of the long arm of chromosome 18, involving a critical region that results in a variable phenotype characterized by growth delay, multisystem malformations, and intellectual disability. We report the case of a 7-month-old male presenting with recurrent respiratory infections. Clinical examination revealed multiple craniofacial and musculoskeletal abnormalities, including tapering fingers, clinodactyly of the right thumb and index finger, bilateral Simian creases, and long toes with overriding of the fourth toe over the fifth. Diagnostic imaging suggested bilateral cryptorchidism and mild ventriculomegaly. Karyotyping confirmed 18q deletion syndrome with the karyotype 46, XY, del(18)(q21.1). This case highlights the broad clinical spectrum of De Grouchy syndrome and emphasizes the importance of precise molecular mapping for genotype–phenotype correlation, early diagnosis, and timely intervention and management.

Open article ↗



2024-11-26 | Rare Maternal Structural Mosaicism as a Familial Cause of 18p Deletion Syndrome: Cytogenetics Mechanisms and Phenotypic Variability

The chromosome 18p deletion (18p-) syndrome or monosomy of 18p is a rare chromosome abnormality, considered a contiguous gene deletion syndrome resulting from the deletion of a portion or most of the whole short arm of chromosome 18. Therefore, it can present a spectrum of phenotypes associated with different prognostic outcomes. Understanding the clinical variability of this condition is important once the fertility is preserved, impacting genetic counseling and reproductive outcomes. The aim of this article is to report a case of familial 18p deletion syndrome and its striking phenotypic variability within the same family. A male stillborn presenting alobar holoprosencephaly and his mother who presented with a single central incisor came to our attention for genetic investigation. Karyotype analysis and Fluorescent In Situ Hybridization (FISH) from a cordocentesis blood sample of the male stillborn was performed. Parents’ cytogenetic analyses were obtained through peripheral blood cultures. Chromosomes were analyzed after GTG banding. FISH technique was carried out on both the proband's and maternal samples using WCP18 (whole chromosome 18) specific probes, according to the manufacturer's protocols. The stillborn karyotype and FISH analysis revealed a deletion characterized by 46, XY del(18)(p11.1→pter).ish del(18)(p11.1→pter)(wcp18-). His mother showed the same deletion in 45% of the analyzed cells revealing a rare structural mosaicism. The striking phenotypic variability encountered in this family could be attributed to a genetic combination of the deleted segment in the proband; and the presence of a mosaic normal karyotype may very well attenuate the mother’s phenotypic presentation. The origin of an abnormally structural chromosome in mosaic possibly originated from a post-zygotic cell division event during the embryonic development of the mother. The consequences on the family offsprings of such rare cytogenetic event impacts greatly the family genetic counseling

Open article ↗



2016-05-31 | Making chromosome abnormalities treatable conditions.

Individuals affected by the classic chromosome deletion syndromes which were first identified at the beginning of the genetic age, are now positioned to benefit from genomic advances. This issue highlights five of these conditions (4p-, 5p-, 11q-, 18p-, and 18q-). It focuses on the increased in understanding of the molecular underpinnings and envisions how these can be transformed into effective treatments. While it is scientifically exciting to see the phenotypic manifestations of hemizygosity being increasingly understood at the molecular and cellular level, it is even more amazing to consider that we are now on the road to making chromosome abnormalities treatable conditions.

Open article ↗



1991-02-20 | Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 5 or 18.

Development of colon carcinomas can be associated with allelic deletions on several chromosomes, including 5q and 18q. The APC gene on 5q and the DCC gene on 18q have been identified as potential tumour suppressor genes, whose suppression contributes to colon carcinogenesis. To investigate the role of genes in these deleted regions, we have now introduced a single normal human chromosome into a human colon carcinoma cell line, COKFu, through microcell hybridization. Several clones of hybrid cells containing normal chromosome 5, and others containing normal chromosome 18, were obtained. The morphology of the hybrid cells was markedly altered: the hybrids with chromosome 5 exhibited a closely packed polygonal morphology, and the hybrid cells with chromosome 18 were flattened. The cloning efficiency of the hybrid cells in soft agar was reduced from 0.46 to 0% of that of the parental carcinoma cells, and the tumorigenicity of these hybrid cells in athymic nude mice was completely suppressed. The growth properties of the hybrid cells with chromosome 11 were not substantially changed. These results strongly suggest that the genes on normal chromosome 5 and 18 function as tumour suppressors in colon carcinogenesis.

Open article ↗



proteins
2024-03-25 | 18q chromosome deletion syndrome associated with growth hormone deficiency

Introdução: A síndrome da deleção do cromossomo 18q é causada pela deleção no braço longo do cromossomo 18 e tem seu fenótipo variável com baixa estatura associada. Relato de caso: pré-escolar, sexo feminino, apresentava comorbidades (cardiopatia congênita, síndrome do lactente sibilante e pé torto congênito bilateral) e fenótipo típico da síndrome da deleção do cromossomo 18q, confirmada pela deleção na porção distal do cromossomo 18 (46, XX, del (18) (q23)) no cariótipo. Apresentava baixa estatura grave (escore Z de estatura inicial - 4,62) com diagnóstico de deficiência de hormônio de crescimento associado, mas teve melhora estatural com o uso de somatropina (escore Z de estatura atual -2,51). Discussão: comorbidades como cardiopatia congênita, uso de glicocorticoides e alterações ortopédicas contribuem significativamente para a baixa estatura em indivíduos afetados por síndromes genéticas, mas a presença de deficiência de hormônio de crescimento associada deve ser investigada para a melhora da estatura final com o uso de somatropina. Conclusão: na síndrome da deleção do cromossomo 18q23, o tratamento precoce da deficiência de hormônio de crescimento e o controle de comorbidades permitem uma melhora importante no ganho estatural dos pacientes.

Open article ↗



2022-02-01 | Subcutaneous immunoglobulin replacement therapy in a patient with 18q deletion syndrome, primary immune deficiency, and type 1 diabetes.

18q deletion syndrome (OMIM #601808) results from a deletion of a part of a long arm of 18 chromosome and is characterized by mental retardation and congenital malformations. We present an exceptional case of a 12-year-old girl with severe phenotype of 18q deletion syndrome, frequent infections, type 1 diabetes, autoimmune thyroiditis, and vitiligo. At first, the patient was diagnosed with selective immunoglobulin A (sIgAD) which explained her susceptibility to both infections and autoimmunity. With time, sIgAD progressed to common variable immune deficiency-like (CVID-like) disorder. She had a minimum of 12 infections per year, approximately twice as many courses of different antibiotics and up to three hospitalizations annually, making the treatment of diabetes difficult. Due to safety issues (increased risk of adverse reaction to blood products) and patient's convenience, subcutaneous IgG (SCIG) replacement therapy was initiated. We noticed a substantial decrease in the number of infections and improvement of metabolic control of diabetes.

Open article ↗



2021-12-09 | Clinical Characteristics and Long-Term Recombinant Human Growth Hormone Treatment of 18q- Syndrome: A Case Report and Literature Review

Background 18q- syndrome is a rare chromosomal disease caused by the deletion of the long arm of chromosome 18. Some cases with 18q- syndrome can be combined with growth hormone deficiency (GHD), but data on the efficacy of recombinant human growth hormone (rhGH) treatment in 18q- syndrome are limited. Methods Here, we report one case of 18q- syndrome successfully treated with long-term rhGH supplement. Previously reported cases in the literature are also reviewed to investigate the karyotype–phenotype relationship and their therapeutic response to rhGH. Results A 7.9-year-old girl was referred for evaluation for short stature. Physical exam revealed proportionally short stature with a height of 111.10 cm (−3.02 SD score (SDS)), low-set ears, a high-arched palate, a small jaw, webbed neck, widely spaced nipples, long and tapering fingers, and cubitus valgus. Thyroid function test indicated subclinical hypothyroidism. The peak value of growth hormone was 10.26 ng/ml in the levodopa provocation test. Insulin-like growth factor 1 (IGF-1) was 126 ng/ml (57–316 ng/ml). Other laboratory investigations, including complete blood cell count, liver and kidney function, gonadal function, serum adrenocorticotropin levels, and serum cortisol levels, were all within normal ranges. Karyotype analysis showed 46, XX, del (18) (q21). L-Thyroxine replacement and rhGH treatment were initiated and maintained in the following 7 years. At the age of 14.8, her height has reached 159.5 cm with a height SDS increase of 2.82 SDS (from −3.02 SDS to −0.20 SDS). No significant side effects were found during the treatment. The literature review indicated the average rhGH treatment duration of 16 patients was 5.9 ± 3.3 years, and the average height SDS significantly increased from −3.12 ± 0.94 SDS to −1.38 ± 1.29 SDS after the rhGH treatment (p < 0.0001). Conclusion The main clinical manifestations of 18q- syndrome include characteristic appearance, intellectual disability, and abnormal genital development. The literature review suggested a significant height benefit for short stature with 18q- syndrome from long-term rhGH treatment.

Open article ↗



2019-08-15 | [Genotypic and phenotypic analysis of a patient with de novo partial monosomy 18p and partial trisomy 18q].

To explore the genetic cause for a patient with intellectual disability, short stature and multiple congenital anomalies, and to correlate the result with the clinical phenotype. Routine karyotyping analysis was carried out on GTG-banded metaphase chromosomes. Single nucleotide polymorphism (SNP) microarray was used to detect microdeletions or microduplications in the patient. Fluorescence in situ hybridization (FISH) was used to ascertain the origin of aberrant chromosomes. The karyotype of the patient was 46,XY,der(18), while both of his parents had a normal karyotype. SNP array identified a 1.23 Mb deletion at 18p11.32-pter (chr18: 136 227-1 370 501, hg19) and a 33.76 Mb duplication at 18q21.1-qter (chr18: 44 250 359-78 013 728, hg19) in the patient. Above finding was confirmed by dual-color FISH with one color for 18p and another for 18q. The patient presented with some common features of 18p deletion and 18q duplication including intellectual disability and growth retardation, in addition with some features of 18p deletion including pectus excavatum, short stature and growth hormone (GH) deficiency. The patient showed progressive improvement of stature with GH therapy. Comparison of patients with previously reported dup(18q)+del(18p) recombinations suggested that, even for patients with similar breakpoints, their phenotypes have ranged from normal to severe and there were no consistent findings. As aberrations involving double chromosomal segments often result in phenotypic variability, it has been difficult to correlate the genotype of our patient with his phenotype.

Open article ↗



2012-10-01 | 739 18Q22 Monosomy: Genotype-Phenotype Correlation and Therapeutic Impact

The deletion of the long arm of chromosome 18 causes a contiguous gene deletion syndrome with a highly variable phenotype, usually related to the extent of the deleted region. The most commonly reported clinical features include: mental disabilities, decreased growth, microcephaly and facial abnormalities. We report on a case with partial monosomy 18q22 derived from a maternal reciprocal translocation t(8; 18). The patient was 7 months old referred for genetic exploration of neurodevelopmental delay, craniofacial dysmorphism, post natal growth retardation, choanal atresia, club foot and congenital hip dislocation. Chromosome analysis from peripheral blood showed a 46, XY, der (18). Array CGH was performed and revealed a partial monosomy 18q21.33q22.31 of 15.3MB associated with partial trisomy 8q24.12q24.23 of 22.7MB region. These results were confirmed by FISH using telomeric 18q probe. Choanal atresia and skeletal malformation are in agreement with the monosomy 18q. Interestingly, the deletion includes GALR1 gene in 18q23 witch encodes galanine receptor. Galanine is a neuromodulator that stimulates growth hormone secretion. MBP, and adjacent genes, are implicated in myelination process and haploinsufficiency explains partially developmental delay. Otherwise, the haploinsufficiency of the 18q22.3-q23 gene region is suggested to be a critical region for the immunoglobuline A deficiency which is significantly associated to celiac disease. Our patient has not until now immunological desorders. The association deletion 18q22- GH deficiency and decreased myelinisation is now well estabilished. The real therapeutic impact of GH treatment is discussed.

Open article ↗



small molecules
2026-06-19 | Catatonia associated with mosaic 18q deletion syndrome: a case report.

Catatonia is increasingly diagnosed in neurodevelopmental disorders, yet most data focus on individuals with autism spectrum disorder. To our knowledge, catatonia has not been reported in association with chromosome 18 deletion syndrome. We describe a 19-year-old woman with a mosaic terminal 18q deletion (18q23) who developed severe catatonia following SARS-CoV-2 infection. She presented with mutism, stupor, negativism, posturing, rigidity, waxy flexibility, and withdrawal. Extensive neurological, infectious, and autoimmune workup, including cerebrospinal fluid analyses, revealed no abnormalities. Electroencephalography (EEG) showed intermittent frontotemporal right-dominant dysfunction, characterized by short clusters of high-amplitude polymorphic theta paroxysms without epileptiform discharges. Symptomatic treatment with lorazepam led to rapid initiation of speech within 24 h and full remission of catatonic features after four days. Follow-up EEG recordings at three and ten months were normal, and no recurrence occurred. This first reported case raises the possibility that individuals with the rare chromosome 18q deletion, including mosaic forms, may be vulnerable to catatonia particularly in the presence of systemic or environmental stressors such as viral infection or environmental change. Awareness of this potential association and early benzodiazepine treatment are critical to prevent complications and facilitate recovery.

Open article ↗



2024-04-30 | 18q Deletion Syndrome-Associated Schizophrenia: A Case Report.

18q deletion syndrome is a rare genetic disorder characterized by various neurodevelopmental anomalies and medical issues. Although the occurrence of psychosis has been reported in a small number of cases, details regarding the nature of such symptoms and their response to treatment have not been described. We describe a 31-year-old male with a history of speech delays, autistic features, a tethered spinal cord, bilateral vertical talus, subaortic stenosis and aortic regurgitation, recurrent otitis media, mild hearing loss, and hypospadias, who experienced a first episode of psychosis in his late 20s. His psychotic symptoms included auditory hallucinations, various delusions, and disorganization of thought. Although his presentation is atypical in certain ways (e.g., exhibiting highly fluctuant symptoms), he nonetheless meets criteria for schizophrenia. Given his overall clinical picture, chromosomal microarray analysis was completed, which revealed a 19.78 Mb deletion at 18q21.32 from nucleotide 58,226,713 to 78,015,180 (GRCh37). Despite exhibiting a somewhat idiosyncratic response to numerous antipsychotic medications, he eventually achieved partial remission of symptoms with improved insight on relatively low dose oral aripiprazole therapy. This is the first in-depth description of 18q deletion syndrome-associated schizophrenia. While our patient's atypical presentation and idiosyncratic response to treatment may be mediated by his comorbid diagnosis of autism, his unusual psychiatric phenotype may alternatively be directly related to his underlying genetic disorder. The description of additional cases in the future will hopefully help clarify matters further.

Open article ↗



2021-12-21 | Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.

Few therapies target the loss of tumor suppressor genes in cancer. We examine CRISPR-SpCas9 and RNA-interference loss-of-function screens to identify new therapeutic targets associated with genomic loss of tumor suppressor genes. The endosomal sorting complexes required for transport (ESCRT) ATPases VPS4A and VPS4B score as strong synthetic lethal dependencies. VPS4A is essential in cancers harboring loss of VPS4B adjacent to SMAD4 on chromosome 18q and VPS4B is required in tumors with co-deletion of VPS4A and CDH1 (E-cadherin) on chromosome 16q. We demonstrate that more than 30% of cancers selectively require VPS4A or VPS4B. VPS4A suppression in VPS4B-deficient cells selectively leads to ESCRT-III filament accumulation, cytokinesis defects, nuclear deformation, G2/M arrest, apoptosis, and potent tumor regression. CRISPR-SpCas9 screening and integrative genomic analysis reveal other ESCRT members, regulators of abscission, and interferon signaling as modifiers of VPS4A dependency. We describe a compendium of synthetic lethal vulnerabilities and nominate VPS4A and VPS4B as high-priority therapeutic targets for cancers with 18q or 16q loss.

Open article ↗



2016-08-05 | Neurodevelopmental models of transcription factor 4 deficiency converge on a common ion channel as a potential therapeutic target for Pitt Hopkins syndrome

The clinically pleiotropic gene, Transcription Factor 4 (TCF4), is a broadly expressed basic helix-loop-helix (bHLH) transcription factor linked to multiple neurodevelopmental disorders, including schizophrenia, 18q deletion syndrome, and Pitt Hopkins syndrome (PTHS). In vivo suppression of Tcf4 by shRNA or mutation by CRISPR/Cas9 in the developing rat prefrontal cortex resulted in attenuated action potential output. To explain this intrinsic excitability deficit, we demonstrated that haploinsufficiency of TCF4 lead to the ectopic expression of two ion channels, Scn10a and Kcnq1. These targets of TCF4 regulation were identified through molecular profiling experiments that used translating ribosome affinity purification to enrich mRNA from genetically manipulated neurons.Using a mouse model of PTHS (Tcf4+/tr), we observed a similar intrinsic excitability deficit, however the underlying mechanism appeared slightly different than our rat model - as Scn10a expression was similarly increased but Kcnq1 expression was decreased. Here, we show that the truncated TCF4 protein expressed in our PTHS mouse model binds to wild-type TCF4 protein, and we suggest the difference in Kcnq1 expression levels between these two rodent models appears to be explained by a dominant-negative function of the truncated TCF4 protein. Despite the differences in the underlying molecular mechanisms, we observed common underlying intrinsic excitability deficits that are consistent with ectopic expression of Scn10a. The converging molecular function of TCF4 across two independent rodent models indicates SCN10a is a potential therapeutic target for Pitt-Hopkins syndrome.

Open article ↗



2011-12-13 | Inflammatory and Noninflammatory Arthropathy in Patients With 18q Deletion Syndrome

A 7-year-old girl with 18q deletion syndrome developed chronic progressive polyarticular inflammatory arthropathy. Atypical features of her arthritis included lack of morning stiffness, absence of pain and discomfort, normal acute-phase reactants, and the presence of clinodactyly, low-set thumbs, metatarsus adductus of her feet, and overriding nontender swollen toes. She had a positive antinuclear antibody test, negative rheumatoid factor and anti–cyclic citrullinated peptide, and undetectable immunoglobulin A level. Magnetic resonance imaging of the right knee and the result of the synovial biopsy were consistent with synovitis. She was treated with naproxen, short course of prednisone, and methotrexate with good clinical response that plateaued over time. We analyzed the scarce reports of inflammatory arthropathy in 18q deletion syndrome and proposed an outline for investigating arthropathies in patients with chromosomal aberrations.

Open article ↗



gene therapies
2026-01-01 | De Grouchy Syndrome (18q Deletion): A Rare Case with Clinical and Genetic Insights

De Grouchy syndrome is a rare chromosomal disorder caused by the deletion of the long arm of chromosome 18, involving a critical region that results in a variable phenotype characterized by growth delay, multisystem malformations, and intellectual disability. We report the case of a 7-month-old male presenting with recurrent respiratory infections. Clinical examination revealed multiple craniofacial and musculoskeletal abnormalities, including tapering fingers, clinodactyly of the right thumb and index finger, bilateral Simian creases, and long toes with overriding of the fourth toe over the fifth. Diagnostic imaging suggested bilateral cryptorchidism and mild ventriculomegaly. Karyotyping confirmed 18q deletion syndrome with the karyotype 46, XY, del(18)(q21.1). This case highlights the broad clinical spectrum of De Grouchy syndrome and emphasizes the importance of precise molecular mapping for genotype–phenotype correlation, early diagnosis, and timely intervention and management.

Open article ↗



2024-11-26 | Rare Maternal Structural Mosaicism as a Familial Cause of 18p Deletion Syndrome: Cytogenetics Mechanisms and Phenotypic Variability

The chromosome 18p deletion (18p-) syndrome or monosomy of 18p is a rare chromosome abnormality, considered a contiguous gene deletion syndrome resulting from the deletion of a portion or most of the whole short arm of chromosome 18. Therefore, it can present a spectrum of phenotypes associated with different prognostic outcomes. Understanding the clinical variability of this condition is important once the fertility is preserved, impacting genetic counseling and reproductive outcomes. The aim of this article is to report a case of familial 18p deletion syndrome and its striking phenotypic variability within the same family. A male stillborn presenting alobar holoprosencephaly and his mother who presented with a single central incisor came to our attention for genetic investigation. Karyotype analysis and Fluorescent In Situ Hybridization (FISH) from a cordocentesis blood sample of the male stillborn was performed. Parents’ cytogenetic analyses were obtained through peripheral blood cultures. Chromosomes were analyzed after GTG banding. FISH technique was carried out on both the proband's and maternal samples using WCP18 (whole chromosome 18) specific probes, according to the manufacturer's protocols. The stillborn karyotype and FISH analysis revealed a deletion characterized by 46, XY del(18)(p11.1→pter).ish del(18)(p11.1→pter)(wcp18-). His mother showed the same deletion in 45% of the analyzed cells revealing a rare structural mosaicism. The striking phenotypic variability encountered in this family could be attributed to a genetic combination of the deleted segment in the proband; and the presence of a mosaic normal karyotype may very well attenuate the mother’s phenotypic presentation. The origin of an abnormally structural chromosome in mosaic possibly originated from a post-zygotic cell division event during the embryonic development of the mother. The consequences on the family offsprings of such rare cytogenetic event impacts greatly the family genetic counseling

Open article ↗



2016-05-31 | Making chromosome abnormalities treatable conditions.

Individuals affected by the classic chromosome deletion syndromes which were first identified at the beginning of the genetic age, are now positioned to benefit from genomic advances. This issue highlights five of these conditions (4p-, 5p-, 11q-, 18p-, and 18q-). It focuses on the increased in understanding of the molecular underpinnings and envisions how these can be transformed into effective treatments. While it is scientifically exciting to see the phenotypic manifestations of hemizygosity being increasingly understood at the molecular and cellular level, it is even more amazing to consider that we are now on the road to making chromosome abnormalities treatable conditions.

Open article ↗



1991-02-20 | Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 5 or 18.

Development of colon carcinomas can be associated with allelic deletions on several chromosomes, including 5q and 18q. The APC gene on 5q and the DCC gene on 18q have been identified as potential tumour suppressor genes, whose suppression contributes to colon carcinogenesis. To investigate the role of genes in these deleted regions, we have now introduced a single normal human chromosome into a human colon carcinoma cell line, COKFu, through microcell hybridization. Several clones of hybrid cells containing normal chromosome 5, and others containing normal chromosome 18, were obtained. The morphology of the hybrid cells was markedly altered: the hybrids with chromosome 5 exhibited a closely packed polygonal morphology, and the hybrid cells with chromosome 18 were flattened. The cloning efficiency of the hybrid cells in soft agar was reduced from 0.46 to 0% of that of the parental carcinoma cells, and the tumorigenicity of these hybrid cells in athymic nude mice was completely suppressed. The growth properties of the hybrid cells with chromosome 11 were not substantially changed. These results strongly suggest that the genes on normal chromosome 5 and 18 function as tumour suppressors in colon carcinogenesis.

Open article ↗



proteins
2024-03-25 | 18q chromosome deletion syndrome associated with growth hormone deficiency

Introdução: A síndrome da deleção do cromossomo 18q é causada pela deleção no braço longo do cromossomo 18 e tem seu fenótipo variável com baixa estatura associada. Relato de caso: pré-escolar, sexo feminino, apresentava comorbidades (cardiopatia congênita, síndrome do lactente sibilante e pé torto congênito bilateral) e fenótipo típico da síndrome da deleção do cromossomo 18q, confirmada pela deleção na porção distal do cromossomo 18 (46, XX, del (18) (q23)) no cariótipo. Apresentava baixa estatura grave (escore Z de estatura inicial - 4,62) com diagnóstico de deficiência de hormônio de crescimento associado, mas teve melhora estatural com o uso de somatropina (escore Z de estatura atual -2,51). Discussão: comorbidades como cardiopatia congênita, uso de glicocorticoides e alterações ortopédicas contribuem significativamente para a baixa estatura em indivíduos afetados por síndromes genéticas, mas a presença de deficiência de hormônio de crescimento associada deve ser investigada para a melhora da estatura final com o uso de somatropina. Conclusão: na síndrome da deleção do cromossomo 18q23, o tratamento precoce da deficiência de hormônio de crescimento e o controle de comorbidades permitem uma melhora importante no ganho estatural dos pacientes.

Open article ↗



2022-02-01 | Subcutaneous immunoglobulin replacement therapy in a patient with 18q deletion syndrome, primary immune deficiency, and type 1 diabetes.

18q deletion syndrome (OMIM #601808) results from a deletion of a part of a long arm of 18 chromosome and is characterized by mental retardation and congenital malformations. We present an exceptional case of a 12-year-old girl with severe phenotype of 18q deletion syndrome, frequent infections, type 1 diabetes, autoimmune thyroiditis, and vitiligo. At first, the patient was diagnosed with selective immunoglobulin A (sIgAD) which explained her susceptibility to both infections and autoimmunity. With time, sIgAD progressed to common variable immune deficiency-like (CVID-like) disorder. She had a minimum of 12 infections per year, approximately twice as many courses of different antibiotics and up to three hospitalizations annually, making the treatment of diabetes difficult. Due to safety issues (increased risk of adverse reaction to blood products) and patient's convenience, subcutaneous IgG (SCIG) replacement therapy was initiated. We noticed a substantial decrease in the number of infections and improvement of metabolic control of diabetes.

Open article ↗



2021-12-09 | Clinical Characteristics and Long-Term Recombinant Human Growth Hormone Treatment of 18q- Syndrome: A Case Report and Literature Review

Background 18q- syndrome is a rare chromosomal disease caused by the deletion of the long arm of chromosome 18. Some cases with 18q- syndrome can be combined with growth hormone deficiency (GHD), but data on the efficacy of recombinant human growth hormone (rhGH) treatment in 18q- syndrome are limited. Methods Here, we report one case of 18q- syndrome successfully treated with long-term rhGH supplement. Previously reported cases in the literature are also reviewed to investigate the karyotype–phenotype relationship and their therapeutic response to rhGH. Results A 7.9-year-old girl was referred for evaluation for short stature. Physical exam revealed proportionally short stature with a height of 111.10 cm (−3.02 SD score (SDS)), low-set ears, a high-arched palate, a small jaw, webbed neck, widely spaced nipples, long and tapering fingers, and cubitus valgus. Thyroid function test indicated subclinical hypothyroidism. The peak value of growth hormone was 10.26 ng/ml in the levodopa provocation test. Insulin-like growth factor 1 (IGF-1) was 126 ng/ml (57–316 ng/ml). Other laboratory investigations, including complete blood cell count, liver and kidney function, gonadal function, serum adrenocorticotropin levels, and serum cortisol levels, were all within normal ranges. Karyotype analysis showed 46, XX, del (18) (q21). L-Thyroxine replacement and rhGH treatment were initiated and maintained in the following 7 years. At the age of 14.8, her height has reached 159.5 cm with a height SDS increase of 2.82 SDS (from −3.02 SDS to −0.20 SDS). No significant side effects were found during the treatment. The literature review indicated the average rhGH treatment duration of 16 patients was 5.9 ± 3.3 years, and the average height SDS significantly increased from −3.12 ± 0.94 SDS to −1.38 ± 1.29 SDS after the rhGH treatment (p < 0.0001). Conclusion The main clinical manifestations of 18q- syndrome include characteristic appearance, intellectual disability, and abnormal genital development. The literature review suggested a significant height benefit for short stature with 18q- syndrome from long-term rhGH treatment.

Open article ↗



2019-08-15 | [Genotypic and phenotypic analysis of a patient with de novo partial monosomy 18p and partial trisomy 18q].

To explore the genetic cause for a patient with intellectual disability, short stature and multiple congenital anomalies, and to correlate the result with the clinical phenotype. Routine karyotyping analysis was carried out on GTG-banded metaphase chromosomes. Single nucleotide polymorphism (SNP) microarray was used to detect microdeletions or microduplications in the patient. Fluorescence in situ hybridization (FISH) was used to ascertain the origin of aberrant chromosomes. The karyotype of the patient was 46,XY,der(18), while both of his parents had a normal karyotype. SNP array identified a 1.23 Mb deletion at 18p11.32-pter (chr18: 136 227-1 370 501, hg19) and a 33.76 Mb duplication at 18q21.1-qter (chr18: 44 250 359-78 013 728, hg19) in the patient. Above finding was confirmed by dual-color FISH with one color for 18p and another for 18q. The patient presented with some common features of 18p deletion and 18q duplication including intellectual disability and growth retardation, in addition with some features of 18p deletion including pectus excavatum, short stature and growth hormone (GH) deficiency. The patient showed progressive improvement of stature with GH therapy. Comparison of patients with previously reported dup(18q)+del(18p) recombinations suggested that, even for patients with similar breakpoints, their phenotypes have ranged from normal to severe and there were no consistent findings. As aberrations involving double chromosomal segments often result in phenotypic variability, it has been difficult to correlate the genotype of our patient with his phenotype.

Open article ↗



2012-10-01 | 739 18Q22 Monosomy: Genotype-Phenotype Correlation and Therapeutic Impact

The deletion of the long arm of chromosome 18 causes a contiguous gene deletion syndrome with a highly variable phenotype, usually related to the extent of the deleted region. The most commonly reported clinical features include: mental disabilities, decreased growth, microcephaly and facial abnormalities. We report on a case with partial monosomy 18q22 derived from a maternal reciprocal translocation t(8; 18). The patient was 7 months old referred for genetic exploration of neurodevelopmental delay, craniofacial dysmorphism, post natal growth retardation, choanal atresia, club foot and congenital hip dislocation. Chromosome analysis from peripheral blood showed a 46, XY, der (18). Array CGH was performed and revealed a partial monosomy 18q21.33q22.31 of 15.3MB associated with partial trisomy 8q24.12q24.23 of 22.7MB region. These results were confirmed by FISH using telomeric 18q probe. Choanal atresia and skeletal malformation are in agreement with the monosomy 18q. Interestingly, the deletion includes GALR1 gene in 18q23 witch encodes galanine receptor. Galanine is a neuromodulator that stimulates growth hormone secretion. MBP, and adjacent genes, are implicated in myelination process and haploinsufficiency explains partially developmental delay. Otherwise, the haploinsufficiency of the 18q22.3-q23 gene region is suggested to be a critical region for the immunoglobuline A deficiency which is significantly associated to celiac disease. Our patient has not until now immunological desorders. The association deletion 18q22- GH deficiency and decreased myelinisation is now well estabilished. The real therapeutic impact of GH treatment is discussed.

Open article ↗



small molecules
2026-06-19 | Catatonia associated with mosaic 18q deletion syndrome: a case report.

Catatonia is increasingly diagnosed in neurodevelopmental disorders, yet most data focus on individuals with autism spectrum disorder. To our knowledge, catatonia has not been reported in association with chromosome 18 deletion syndrome. We describe a 19-year-old woman with a mosaic terminal 18q deletion (18q23) who developed severe catatonia following SARS-CoV-2 infection. She presented with mutism, stupor, negativism, posturing, rigidity, waxy flexibility, and withdrawal. Extensive neurological, infectious, and autoimmune workup, including cerebrospinal fluid analyses, revealed no abnormalities. Electroencephalography (EEG) showed intermittent frontotemporal right-dominant dysfunction, characterized by short clusters of high-amplitude polymorphic theta paroxysms without epileptiform discharges. Symptomatic treatment with lorazepam led to rapid initiation of speech within 24 h and full remission of catatonic features after four days. Follow-up EEG recordings at three and ten months were normal, and no recurrence occurred. This first reported case raises the possibility that individuals with the rare chromosome 18q deletion, including mosaic forms, may be vulnerable to catatonia particularly in the presence of systemic or environmental stressors such as viral infection or environmental change. Awareness of this potential association and early benzodiazepine treatment are critical to prevent complications and facilitate recovery.

Open article ↗



2024-04-30 | 18q Deletion Syndrome-Associated Schizophrenia: A Case Report.

18q deletion syndrome is a rare genetic disorder characterized by various neurodevelopmental anomalies and medical issues. Although the occurrence of psychosis has been reported in a small number of cases, details regarding the nature of such symptoms and their response to treatment have not been described. We describe a 31-year-old male with a history of speech delays, autistic features, a tethered spinal cord, bilateral vertical talus, subaortic stenosis and aortic regurgitation, recurrent otitis media, mild hearing loss, and hypospadias, who experienced a first episode of psychosis in his late 20s. His psychotic symptoms included auditory hallucinations, various delusions, and disorganization of thought. Although his presentation is atypical in certain ways (e.g., exhibiting highly fluctuant symptoms), he nonetheless meets criteria for schizophrenia. Given his overall clinical picture, chromosomal microarray analysis was completed, which revealed a 19.78 Mb deletion at 18q21.32 from nucleotide 58,226,713 to 78,015,180 (GRCh37). Despite exhibiting a somewhat idiosyncratic response to numerous antipsychotic medications, he eventually achieved partial remission of symptoms with improved insight on relatively low dose oral aripiprazole therapy. This is the first in-depth description of 18q deletion syndrome-associated schizophrenia. While our patient's atypical presentation and idiosyncratic response to treatment may be mediated by his comorbid diagnosis of autism, his unusual psychiatric phenotype may alternatively be directly related to his underlying genetic disorder. The description of additional cases in the future will hopefully help clarify matters further.

Open article ↗



2021-12-21 | Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.

Few therapies target the loss of tumor suppressor genes in cancer. We examine CRISPR-SpCas9 and RNA-interference loss-of-function screens to identify new therapeutic targets associated with genomic loss of tumor suppressor genes. The endosomal sorting complexes required for transport (ESCRT) ATPases VPS4A and VPS4B score as strong synthetic lethal dependencies. VPS4A is essential in cancers harboring loss of VPS4B adjacent to SMAD4 on chromosome 18q and VPS4B is required in tumors with co-deletion of VPS4A and CDH1 (E-cadherin) on chromosome 16q. We demonstrate that more than 30% of cancers selectively require VPS4A or VPS4B. VPS4A suppression in VPS4B-deficient cells selectively leads to ESCRT-III filament accumulation, cytokinesis defects, nuclear deformation, G2/M arrest, apoptosis, and potent tumor regression. CRISPR-SpCas9 screening and integrative genomic analysis reveal other ESCRT members, regulators of abscission, and interferon signaling as modifiers of VPS4A dependency. We describe a compendium of synthetic lethal vulnerabilities and nominate VPS4A and VPS4B as high-priority therapeutic targets for cancers with 18q or 16q loss.

Open article ↗



2016-08-05 | Neurodevelopmental models of transcription factor 4 deficiency converge on a common ion channel as a potential therapeutic target for Pitt Hopkins syndrome

The clinically pleiotropic gene, Transcription Factor 4 (TCF4), is a broadly expressed basic helix-loop-helix (bHLH) transcription factor linked to multiple neurodevelopmental disorders, including schizophrenia, 18q deletion syndrome, and Pitt Hopkins syndrome (PTHS). In vivo suppression of Tcf4 by shRNA or mutation by CRISPR/Cas9 in the developing rat prefrontal cortex resulted in attenuated action potential output. To explain this intrinsic excitability deficit, we demonstrated that haploinsufficiency of TCF4 lead to the ectopic expression of two ion channels, Scn10a and Kcnq1. These targets of TCF4 regulation were identified through molecular profiling experiments that used translating ribosome affinity purification to enrich mRNA from genetically manipulated neurons.Using a mouse model of PTHS (Tcf4+/tr), we observed a similar intrinsic excitability deficit, however the underlying mechanism appeared slightly different than our rat model - as Scn10a expression was similarly increased but Kcnq1 expression was decreased. Here, we show that the truncated TCF4 protein expressed in our PTHS mouse model binds to wild-type TCF4 protein, and we suggest the difference in Kcnq1 expression levels between these two rodent models appears to be explained by a dominant-negative function of the truncated TCF4 protein. Despite the differences in the underlying molecular mechanisms, we observed common underlying intrinsic excitability deficits that are consistent with ectopic expression of Scn10a. The converging molecular function of TCF4 across two independent rodent models indicates SCN10a is a potential therapeutic target for Pitt-Hopkins syndrome.

Open article ↗



2011-12-13 | Inflammatory and Noninflammatory Arthropathy in Patients With 18q Deletion Syndrome

A 7-year-old girl with 18q deletion syndrome developed chronic progressive polyarticular inflammatory arthropathy. Atypical features of her arthritis included lack of morning stiffness, absence of pain and discomfort, normal acute-phase reactants, and the presence of clinodactyly, low-set thumbs, metatarsus adductus of her feet, and overriding nontender swollen toes. She had a positive antinuclear antibody test, negative rheumatoid factor and anti–cyclic citrullinated peptide, and undetectable immunoglobulin A level. Magnetic resonance imaging of the right knee and the result of the synovial biopsy were consistent with synovitis. She was treated with naproxen, short course of prednisone, and methotrexate with good clinical response that plateaued over time. We analyzed the scarce reports of inflammatory arthropathy in 18q deletion syndrome and proposed an outline for investigating arthropathies in patients with chromosomal aberrations.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.